UB
Publicaties op Oncologisch.com
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple ...
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Mul...
Elotuzumab plus VRd plus ASCT bij myeloom: GMMG-HD6 fase III
Isatuximab plus VRd als inductie bij transplanteerbaar myeloom: GMMG-HD7 fase III